IBDEI0YI ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,15581,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,15581,1,1,0)
 ;;=1^Comprehensive,High MDM
 ;;^UTILITY(U,$J,358.3,15581,1,2,0)
 ;;=2^99245
 ;;^UTILITY(U,$J,358.3,15582,0)
 ;;=99395^^60^757^1
 ;;^UTILITY(U,$J,358.3,15582,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,15582,1,1,0)
 ;;=1^Preventive Med,Est Pt,18-39
 ;;^UTILITY(U,$J,358.3,15582,1,2,0)
 ;;=2^99395
 ;;^UTILITY(U,$J,358.3,15583,0)
 ;;=99396^^60^757^2
 ;;^UTILITY(U,$J,358.3,15583,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,15583,1,1,0)
 ;;=1^Preventive Med,Est Pt,40-64
 ;;^UTILITY(U,$J,358.3,15583,1,2,0)
 ;;=2^99396
 ;;^UTILITY(U,$J,358.3,15584,0)
 ;;=99397^^60^757^3
 ;;^UTILITY(U,$J,358.3,15584,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,15584,1,1,0)
 ;;=1^Preventive Med,Est Pt > 64
 ;;^UTILITY(U,$J,358.3,15584,1,2,0)
 ;;=2^99397
 ;;^UTILITY(U,$J,358.3,15585,0)
 ;;=99385^^60^758^1
 ;;^UTILITY(U,$J,358.3,15585,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,15585,1,1,0)
 ;;=1^Preventive Med,New Pt,18-39
 ;;^UTILITY(U,$J,358.3,15585,1,2,0)
 ;;=2^99385
 ;;^UTILITY(U,$J,358.3,15586,0)
 ;;=99386^^60^758^2
 ;;^UTILITY(U,$J,358.3,15586,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,15586,1,1,0)
 ;;=1^Preventive Med,New Pt,40-64
 ;;^UTILITY(U,$J,358.3,15586,1,2,0)
 ;;=2^99386
 ;;^UTILITY(U,$J,358.3,15587,0)
 ;;=99387^^60^758^3
 ;;^UTILITY(U,$J,358.3,15587,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,15587,1,1,0)
 ;;=1^Preventive Med,New Pt > 64
 ;;^UTILITY(U,$J,358.3,15587,1,2,0)
 ;;=2^99387
 ;;^UTILITY(U,$J,358.3,15588,0)
 ;;=99495^^60^759^1
 ;;^UTILITY(U,$J,358.3,15588,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,15588,1,1,0)
 ;;=1^TCM Svc w/in 14 days of D/C w/ Mod MDM
 ;;^UTILITY(U,$J,358.3,15588,1,2,0)
 ;;=2^99495
 ;;^UTILITY(U,$J,358.3,15589,0)
 ;;=99496^^60^759^2
 ;;^UTILITY(U,$J,358.3,15589,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,15589,1,1,0)
 ;;=1^TCM Svc w/in 7 days of D/C w/ High MDM
 ;;^UTILITY(U,$J,358.3,15589,1,2,0)
 ;;=2^99496
 ;;^UTILITY(U,$J,358.3,15589,3,0)
 ;;=^357.33
 ;;^UTILITY(U,$J,358.3,15590,0)
 ;;=B18.2^^61^760^40
 ;;^UTILITY(U,$J,358.3,15590,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15590,1,3,0)
 ;;=3^Hepatitis C,Chr
 ;;^UTILITY(U,$J,358.3,15590,1,4,0)
 ;;=4^B18.2
 ;;^UTILITY(U,$J,358.3,15590,2)
 ;;=^5000548
 ;;^UTILITY(U,$J,358.3,15591,0)
 ;;=E11.9^^61^760^25
 ;;^UTILITY(U,$J,358.3,15591,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15591,1,3,0)
 ;;=3^Diabetes Type 2
 ;;^UTILITY(U,$J,358.3,15591,1,4,0)
 ;;=4^E11.9
 ;;^UTILITY(U,$J,358.3,15591,2)
 ;;=^5002666
 ;;^UTILITY(U,$J,358.3,15592,0)
 ;;=E11.40^^61^760^23
 ;;^UTILITY(U,$J,358.3,15592,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15592,1,3,0)
 ;;=3^DM Type 2 w/ Neuropathy
 ;;^UTILITY(U,$J,358.3,15592,1,4,0)
 ;;=4^E11.40
 ;;^UTILITY(U,$J,358.3,15592,2)
 ;;=^5002644
 ;;^UTILITY(U,$J,358.3,15593,0)
 ;;=E78.2^^61^760^41
 ;;^UTILITY(U,$J,358.3,15593,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15593,1,3,0)
 ;;=3^Hyperlipidemia,Mixed
 ;;^UTILITY(U,$J,358.3,15593,1,4,0)
 ;;=4^E78.2
 ;;^UTILITY(U,$J,358.3,15593,2)
 ;;=^78424
 ;;^UTILITY(U,$J,358.3,15594,0)
 ;;=E78.5^^61^760^42
 ;;^UTILITY(U,$J,358.3,15594,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15594,1,3,0)
 ;;=3^Hyperlipidemia,Unspec
 ;;^UTILITY(U,$J,358.3,15594,1,4,0)
 ;;=4^E78.5
 ;;^UTILITY(U,$J,358.3,15594,2)
 ;;=^5002969
 ;;^UTILITY(U,$J,358.3,15595,0)
 ;;=E66.3^^61^760^59
 ;;^UTILITY(U,$J,358.3,15595,1,0)
 ;;=^358.31IA^4^2
